AU2021412785A1 - Methods of treating psychiatric disorders in obese patients with brexpiprazole - Google Patents
Methods of treating psychiatric disorders in obese patients with brexpiprazole Download PDFInfo
- Publication number
- AU2021412785A1 AU2021412785A1 AU2021412785A AU2021412785A AU2021412785A1 AU 2021412785 A1 AU2021412785 A1 AU 2021412785A1 AU 2021412785 A AU2021412785 A AU 2021412785A AU 2021412785 A AU2021412785 A AU 2021412785A AU 2021412785 A1 AU2021412785 A1 AU 2021412785A1
- Authority
- AU
- Australia
- Prior art keywords
- brexpiprazole
- dose
- day
- days
- cyp2d6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 title claims abstract description 638
- 229960001210 brexpiprazole Drugs 0.000 title claims abstract description 594
- 238000000034 method Methods 0.000 title claims abstract description 108
- 208000020016 psychiatric disease Diseases 0.000 title description 6
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims abstract description 266
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims abstract description 262
- 238000011282 treatment Methods 0.000 claims abstract description 139
- 230000000977 initiatory effect Effects 0.000 claims abstract description 77
- 208000024714 major depressive disease Diseases 0.000 claims abstract description 76
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 76
- 210000000577 adipose tissue Anatomy 0.000 claims description 156
- 230000001225 therapeutic effect Effects 0.000 description 49
- 230000036470 plasma concentration Effects 0.000 description 41
- 229940011389 rexulti Drugs 0.000 description 36
- 230000000694 effects Effects 0.000 description 29
- 208000008589 Obesity Diseases 0.000 description 25
- 235000020824 obesity Nutrition 0.000 description 25
- 208000034332 Body integrity dysphoria Diseases 0.000 description 23
- 210000002381 plasma Anatomy 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 108700028369 Alleles Proteins 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- 206010033307 Overweight Diseases 0.000 description 7
- 208000001431 Psychomotor Agitation Diseases 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 206010001540 Akathisia Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000007220 Cytochrome P-450 CYP2D6 Inhibitors Diseases 0.000 description 4
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 description 3
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 238000011360 adjunctive therapy Methods 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- 229940127236 atypical antipsychotics Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010049119 Emotional distress Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010042464 Suicide attempt Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000037058 blood plasma level Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 101150010738 CYP2D6 gene Proteins 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 1
- 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000024196 oppositional defiant disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000628 reference dose Toxicity 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/139,690 US20220202810A1 (en) | 2020-12-31 | 2020-12-31 | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| US17/139,627 US11229644B1 (en) | 2020-12-31 | 2020-12-31 | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| US17/139,627 | 2020-12-31 | ||
| US17/139,690 | 2020-12-31 | ||
| PCT/US2021/016329 WO2022146462A1 (fr) | 2020-12-31 | 2021-02-03 | Méthodes de traitement de troubles psychiatriques par brexpiprazole chez des patients obèses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021412785A1 true AU2021412785A1 (en) | 2023-06-22 |
Family
ID=82259620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021412785A Pending AU2021412785A1 (en) | 2020-12-31 | 2021-02-03 | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4271381A1 (fr) |
| JP (1) | JP2024502431A (fr) |
| AU (1) | AU2021412785A1 (fr) |
| CA (1) | CA3201123A1 (fr) |
| WO (1) | WO2022146462A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11229644B1 (en) | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| WO2023141634A2 (fr) * | 2022-01-24 | 2023-07-27 | Lake O'hara Llc | Méthodes de traitement à base de brexpiprazole chez des patients obèses atteints de troubles psychiatriques |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015010971A (es) * | 2013-02-27 | 2015-10-26 | Mochida Pharm Co Ltd | Derivado novedoso de pirazol. |
| EP4082546A1 (fr) * | 2017-05-16 | 2022-11-02 | Bow River LLC | Procédés de traitement avec des médicaments à base de substrat du cyp3a4 |
| WO2020132522A1 (fr) * | 2018-12-21 | 2020-06-25 | The Regents Of The University Of California | Traitement de troubles neurodéveloppementaux |
-
2021
- 2021-02-03 CA CA3201123A patent/CA3201123A1/fr active Pending
- 2021-02-03 AU AU2021412785A patent/AU2021412785A1/en active Pending
- 2021-02-03 JP JP2023540740A patent/JP2024502431A/ja active Pending
- 2021-02-03 WO PCT/US2021/016329 patent/WO2022146462A1/fr active Application Filing
- 2021-02-03 EP EP21916093.4A patent/EP4271381A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4271381A1 (fr) | 2023-11-08 |
| JP2024502431A (ja) | 2024-01-19 |
| CA3201123A1 (fr) | 2022-07-07 |
| WO2022146462A1 (fr) | 2022-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Horrigan et al. | A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1) | |
| Kratochvil et al. | Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms | |
| JP6193592B2 (ja) | ピルフェニドン療法を施す方法 | |
| EP4271381A1 (fr) | Méthodes de traitement de troubles psychiatriques par brexpiprazole chez des patients obèses | |
| JP2021119189A (ja) | ジストニアを治療するためのプリドピジンの使用 | |
| JP2023075247A (ja) | ウィルソン病を治療するためのビスコリンテトラチオモリブデート | |
| US11951105B2 (en) | Methods of treating psychiatric disorders in obese patients with brexpiprazole | |
| US20230414606A1 (en) | Methods of treating psychiatric disorders in obese patients with brexpiprazole | |
| US20220202810A1 (en) | Methods of treating psychiatric disorders in obese patients with brexpiprazole | |
| JP2023171774A (ja) | ゴーシェ病を処置する方法 | |
| Elmokadem et al. | Brexpiprazole pharmacokinetics in CYP2D6 poor metabolizers: using physiologically based pharmacokinetic modeling to optimize time to effective concentrations | |
| Mccullough et al. | A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra®) for erectile dysfunction | |
| JP7436524B2 (ja) | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 | |
| US10398691B2 (en) | Methods of treating depression | |
| JP2018177773A (ja) | 医薬 | |
| CA3048206C (fr) | Mise en transition de patients de la vortioxetine a un inhibiteur de monoamine oxydase | |
| WO2019004465A1 (fr) | Composition pharmaceutique contenant du pémafibrate | |
| US20230346718A1 (en) | Method of treating, ameliorating and/or preventing depression | |
| Baldinger et al. | Atomoxetine: a nonstimulant therapeutic option for children and adults with attention-deficit hyperactivity disorder.(Focus on...) | |
| Mancano | New drugs of 2012, part I | |
| WO2013002313A1 (fr) | Médicament destiné à la régulation du poids |